Published in Managed Care Law Weekly, December 4th, 2005
"Canine non-Hodgkin lymphoma (NHL) is considered to be a good animal model for its human counterpart; nevertheless, comparative data on neoangiogenesis are completely lacking," investigators in Italy report.
"The aim of this study is to investigate the levels of serum vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) 2 and 9 in lymphoma-affected dogs," said F. Gentilini and colleagues, University of Bologna.
According to researchers, "circulating levels of VEGF and both MMP 2 and 9 activities significantly correlate with the WHO substage...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.